Quick Answer
Benitec Biopharma Inc. reported Operating Income Loss of -$41.77 million for the year ending 2025.
- Benitec Biopharma Inc. showed a decrease of -85.7% in Operating Income Loss from 2024 to 2025.
- This data is from Benitec Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on September 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$1.17 million | Q4 2019: -$2.11 million | Q1 2020: -$2.11 million | Q3 2020: -$2.69 million | Q4 2020: -$3.26 million | Q1 2021: -$3.79 million | Q3 2021: -$4.82 million | Q4 2021: -$4.84 million | Q1 2022: -$3.46 million | Q3 2022: -$4.58 million | Q4 2022: -$5.61 million | Q1 2023: -$4.34 million | Q3 2023: -$5.87 million | Q4 2023: -$6.93 million | Q1 2024: -$4.14 million | Q3 2024: -$5.79 million | Q4 2024: -$10.81 million | Q1 2025: -$10.19 million | Q2 2025: -$9.83 million | Q3 2025: -$9.80 million | Q4 2025: -$13.38 million.
- Over the full 7 years of available data (2019 to 2025), Benitec Biopharma Inc.'s Operating Income Loss has declined by 1,716.9%.
- Historical annual values: Fiscal year 2025: -$41.77 million | Fiscal year 2024: -$22.49 million | Fiscal year 2023: -$19.08 million | Fiscal year 2022: -$17.85 million | Fiscal year 2021: -$13.60 million | Fiscal year 2020: -$8.28 million | Fiscal year 2019: $2.58 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: